Thierney Biosciences and DHS enter into a $450M Strategic Financing Collaboration: Fernando Aguirre, Vice Chairman to Oversee Operations
WASHINGTON, DISTRICT OF COLUMBIA — Monday, August 16, 2021 — Thierney Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases and DHS Group Equity Partners, today announced that they have entered into a strategic financing collaboration where funds managed by DHS have agreed to provide […] Continue Reading